Izeradjene Kamel, Douglas Leslie, Delaney Addison, Houghton Janet A
Division of Molecular Therapeutics, Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Clin Cancer Res. 2004 Oct 1;10(19):6650-60. doi: 10.1158/1078-0432.CCR-04-0576.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis via the death receptors DR4 and DR5 in transformed cells in vitro and exhibits potent antitumor activity in vivo with minor side effects. Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli and is aberrantly elevated in a variety of human cancers. Rhabdomyosarcoma tumors are the most common soft-tissue sarcoma in childhood. In this investigation, we demonstrate that CK2 is a key survival factor that protects tumor cells from TRAIL-induced apoptosis. We have demonstrated that inhibition of CK2 phosphorylation events by 5,6-dichlorobenzimidazole (DRB) resulted in dramatic sensitization of tumor cells to TRAIL-induced apoptosis. CK2 inhibition also induced rapid cleavage of caspase-8, -9, and -3, as well as the caspase substrate poly(ADP-ribose) polymerase after TRAIL treatment. Overexpression of Bcl-2 protected cells from TRAIL-induced apoptosis in the presence of the CK2 inhibitor. Death signaling by TRAIL in these cells was Fas-associated death domain and caspase dependent because dominant negative Fas-associated death domain or the cowpox interleukin 1beta-converting enzyme inhibitor protein cytokine response modifier A prevented apoptosis in the presence of DRB. Analysis of death-inducing signaling complex (DISC) formation demonstrated that inhibition of CK2 by DRB increased the level of recruitment of procaspase-8 to the DISC and enhanced caspase-8-mediated cleavage of Bid, thereby increasing the release of the proapoptotic factors cytochrome c, HtrA2/Omi, Smac/DIABLO, and apoptosis inducing factor (AIF) from the mitochondria, with subsequent degradation of X-linked inhibitor of apoptosis protein (XIAP). To further interfere with CK2 function, JR1 and Rh30 cells were transfected with either short hairpin RNA targeted to CK2alpha or kinase-inactive CK2alpha (K68M) or CK2alpha' (K69M). Data show that the CK2 kinase activity was abrogated and that TRAIL sensitivity in both cell lines was increased. Silencing of CK2alpha expression with short hairpin RNA was also associated with degradation of XIAP. These findings suggest that CK2 regulates TRAIL signaling in rhabdomyosarcoma by modulating TRAIL-induced DISC formation and XIAP expression.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)在体外通过死亡受体DR4和DR5诱导转化细胞凋亡,并在体内表现出强大的抗肿瘤活性且副作用较小。蛋白激酶酪蛋白激酶II(CK2)会响应多种生长刺激而增加,并且在多种人类癌症中异常升高。横纹肌肉瘤肿瘤是儿童期最常见的软组织肉瘤。在本研究中,我们证明CK2是保护肿瘤细胞免受TRAIL诱导凋亡的关键生存因子。我们已经证明,5,6 - 二氯苯并咪唑(DRB)对CK2磷酸化事件的抑制导致肿瘤细胞对TRAIL诱导的凋亡显著敏感。CK2抑制还在TRAIL处理后诱导了半胱天冬酶 - 8、 - 9和 - 3以及半胱天冬酶底物聚(ADP - 核糖)聚合酶的快速切割。在存在CK2抑制剂的情况下,Bcl - 2的过表达保护细胞免受TRAIL诱导的凋亡。TRAIL在这些细胞中的死亡信号传导是Fas相关死亡结构域和半胱天冬酶依赖性的,因为显性负性Fas相关死亡结构域或牛痘白细胞介素1β转换酶抑制剂蛋白细胞因子反应调节剂A在存在DRB的情况下可防止细胞凋亡。对死亡诱导信号复合物(DISC)形成的分析表明,DRB对CK2的抑制增加了procaspase - 8募集到DISC的水平,并增强了半胱天冬酶 - 8介导的Bid切割,从而增加了促凋亡因子细胞色素c、HtrA2 / Omi(丝氨酸蛋白酶Omi)、Smac / DIABLO(第二线粒体衍生激活因子)和凋亡诱导因子(AIF)从线粒体的释放,随后X连锁凋亡抑制蛋白(XIAP)降解。为了进一步干扰CK2功能,可以用靶向CK2α的短发夹RNA或激酶失活的CK2α(K68M)或CK2α'(K69M)转染JR1和Rh30细胞。数据显示CK2激酶活性被消除,并且两种细胞系对TRAIL的敏感性均增加。用短发夹RNA沉默CK2α表达也与XIAP的降解有关。这些发现表明,CK2通过调节TRAIL诱导的DISC形成和XIAP表达来调节横纹肌肉瘤中的TRAIL信号传导。